PD L1 News and Research

RSS
Ifinatamab deruxtecan shows promising results in advanced small cell lung cancer

Ifinatamab deruxtecan shows promising results in advanced small cell lung cancer

Auburn University researchers develop AI-driven method to target cancer proteins

Auburn University researchers develop AI-driven method to target cancer proteins

Advancing cancer therapy with small molecule immune checkpoint inhibitors

Advancing cancer therapy with small molecule immune checkpoint inhibitors

Advances in precision medicine enhance cancer immunotherapy

Advances in precision medicine enhance cancer immunotherapy

EZH2's role in cancer progression and therapy explored

EZH2's role in cancer progression and therapy explored

Review of fasting-mimicking diets in cancer treatment

Review of fasting-mimicking diets in cancer treatment

New target identified for melanoma resistant to current therapies

New target identified for melanoma resistant to current therapies

FDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancer

FDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancer

Researchers discover key functions of IRF1 in cancer progression and treatment response

Researchers discover key functions of IRF1 in cancer progression and treatment response

Researchers identify shared molecular mechanism in cancer and pregnancy that suppresses immune system

Researchers identify shared molecular mechanism in cancer and pregnancy that suppresses immune system

Advancements in immunotherapy for hepatocellular carcinoma offer hope to patients

Advancements in immunotherapy for hepatocellular carcinoma offer hope to patients

Canagliflozin enhances senescent cell clearance, improving aging-related conditions

Canagliflozin enhances senescent cell clearance, improving aging-related conditions

Study examines the cost-effectiveness of a targeted immunotherapy for lung cancer

Study examines the cost-effectiveness of a targeted immunotherapy for lung cancer

Canagliflozin: A breakthrough in senolytic treatment for aging-related diseases

Canagliflozin: A breakthrough in senolytic treatment for aging-related diseases

Review highlights the rapidly evolving landscape of hepatocellular carcinoma treatment

Review highlights the rapidly evolving landscape of hepatocellular carcinoma treatment

New biomarker predicts immunotherapy response in gastrointestinal cancers

New biomarker predicts immunotherapy response in gastrointestinal cancers

Siblings with unique gene mutation offer insights into type 1 diabetes treatment

Siblings with unique gene mutation offer insights into type 1 diabetes treatment

Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy

Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy

Blood-based DNA test spares bladder cancer patients from unnecessary treatments

Blood-based DNA test spares bladder cancer patients from unnecessary treatments

Focusing on oncogenic driver mutations and resistance mechanisms in the treatment of NSCLC

Focusing on oncogenic driver mutations and resistance mechanisms in the treatment of NSCLC

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.